Bernd Bokemeyer (B Bokemeyer)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 20

Top Topics

Ulcerative Colitis

Top Venues

Alimentary pharmacology & therapeutics

International journal of colorectal disease

Inflammatory bowel diseases

JMIR research protocols

This page only lists publications with an associated author ORCID identifier.

Publications

Bernd Bokemeyer, Sandra Plachta-Danielzik, Isa Maria Steiner, Daniela Pohlschneider, Eugen Urzica, Petra Hartmann, Jennifer Zemke, Ulrich Tappe, Stefan Schreiber, Nadine Steinkat, Jana Langbrandtner, Angelika Hüppe, Tom Stargardt
Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD BIO-ASSIST study). Alimentary pharmacology & therapeutics 59 (9) (2024)
Bernd Bokemeyer, Sandra Plachta-Danielzik, Isa Maria Steiner, Daniela Pohlschneider, Eugen Urzica, Petra Hartmann, Jennifer Zemke, Ulrich Tappe, Stefan Schreiber, Nadine Steinkat, Jana Langbrandtner, Angelika Hüppe, Tom Stargardt
Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD BIO-ASSIST study). Alimentary pharmacology & therapeutics 59 (9) (2024)
Bernd Bokemeyer, Sandra Plachta-Danielzik, Isa Maria Steiner, Daniela Pohlschneider, Eugen Urzica, Petra Hartmann, Jennifer Zemke, Ulrich Tappe, Stefan Schreiber, Nadine Steinkat, Jana Langbrandtner, Angelika Hüppe, Tom Stargardt
Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD BIO-ASSIST study). Alimentary pharmacology & therapeutics (2024)
Eman Al Sulais, Edouard Louis, Bernd Bokemeyer, Krisztina B Gecse, Gareth C Parkes, Miles Parkes, Christian Selinger, Melvin Munsaka, Meng Liu, James Crooks, Tricia Finney-Hayward, Tim Raine
Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory Bowel Disease as Reported Between Adverse Event Reporting Systems and a Patient Questionnaire. Journal of Crohn's & colitis (2024)
Bernd Bokemeyer, Sandra Plachta-Danielzik, Isa Maria Steiner, Daniela Pohlschneider, Eugen Urzica, Petra Hartmann, Jennifer Zemke, Ulrich Tappe, Stefan Schreiber, Nadine Steinkat, Jana Langbrandtner, Angelika Hüppe, Tom Stargardt
Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD BIO-ASSIST study). Alimentary pharmacology & therapeutics 59 (9) (2024)
Bernd Bokemeyer, Sandra Plachta-Danielzik, Isa Maria Steiner, Daniela Pohlschneider, Eugen Urzica, Petra Hartmann, Jennifer Zemke, Ulrich Tappe, Stefan Schreiber, Nadine Steinkat, Jana Langbrandtner, Angelika Hüppe, Tom Stargardt
Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD BIO-ASSIST study). Alimentary pharmacology & therapeutics 59 (9) (2024)
Wolfgang Kruis, Bernd Bokemeyer, Petra Jessen, Mark Hoesl, Michael Mroß, Julia Morgenstern, Birgitta Reimers, Nike Müller-Grage, Ludger Leifeld
Prospective Evaluation of the Prediction Score for a Mild Course of Crohn's Disease (PreMiCC) in Newly Diagnosed Patients With Crohn's Disease: The PROGNOS Study. Inflammatory bowel diseases (2024)
Bernd Bokemeyer, Sandra Plachta-Danielzik, Romina di Giuseppe, Philipp Efken, Wolfgang Mohl, Martin Hoffstadt, Thomas Krause, Axel Schweitzer, Elisabeth Schnoy, Raja Atreya, Niels Teich, Leo Trentmann, Robert Ehehalt, Petra Hartmann, Stefan Schreiber
Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study. Inflammatory bowel diseases (2023)
Bernd Bokemeyer, Sandra Plachta-Danielzik
Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-It depends on how you use the drug. Authors' reply. Alimentary pharmacology & therapeutics (2023)
Isa Maria Steiner, Bernd Bokemeyer, Tom Stargardt
Mapping from SIBDQ to EQ-5D-5L for patients with inflammatory bowel disease. The European journal of health economics : HEPAC : health economics in prevention and care (2023)
Bernd Bokemeyer, Nils Picker, Daniel Kromer, Ludger Rosin, Haridarshan Patel
Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany. International journal of colorectal disease 38 (1) (2023)
Bernd Bokemeyer, Sandra Plachta-Danielzik, Romina di Giuseppe, Ulf Helwig, Niels Teich, Carsten Schmidt, Petra Hartmann, Christina Sobotzki, Stefan Schreiber
Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5-year follow-up data from the prospective BioCrohn study. Alimentary pharmacology & therapeutics (2023)
Bernd Bokemeyer, Nils Picker, Daniel Kromer, Ludger Rosin, Haridarshan Patel
Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany. International journal of colorectal disease 38 (1) (2023)
Bernd Bokemeyer, Sandra Plachta-Danielzik, Romina di Giuseppe, Wolfgang Mohl, Niels Teich, Martin Hoffstadt, Axel Schweitzer, Manfred von der Ohe, Annika Gauss, Raja Atreya, Thomas Krause, Irina Blumenstein, Petra Hartmann, Stefan Schreiber, null null
Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study. Inflammatory bowel diseases (2023)
Bernd Bokemeyer, Tibor Hlavaty, Matthieu Allez, Pamela Selema, Shahrzad Moosavi, Mary Jane Cadatal, Heather Fowler, Markus Mueller, Katherine F Liau, Francisco Javier García-Alonso
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD). Expert opinion on biological therapy (2023)
Bernd Bokemeyer, Nils Picker, Daniel Kromer, Ludger Rosin, Haridarshan Patel
Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany. International journal of colorectal disease 38 (1) (2023)
Sandra Plachta-Danielzik, Lena Grasskemper, Karen Schmidt, Stefan Schreiber, Bernd Bokemeyer
Health Status, Quality of Life, Psychosocial Well-being, and Wearables Data of Patients With Active Ulcerative Colitis Receiving Filgotinib Therapy (FilgoColitis Study): Protocol for a Real-world Observational Study. JMIR research protocols 12 (2023)
Bernd Bokemeyer, Sandra Plachta-Danielzik, Romina di Giuseppe, Philipp Efken, Wolfgang Mohl, Thomas Krause, Martin Hoffstadt, Robert Ehehalt, Leo Trentmann, Axel Schweitzer, Petra Jessen, Petra Hartmann, Stefan Schreiber
Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDO IBD -study. Alimentary pharmacology & therapeutics (2023)
Bernd Bokemeyer, Nils Picker, Thomas Wilke, Ludger Rosin, Haridarshan Patel
Inadequate Response, Treatment Patterns, Health Care Utilization, and Associated Costs in Patients With Ulcerative Colitis: Retrospective Cohort Study Based on German Claims Data. Inflammatory bowel diseases 28 (11) (2022)
Bernd Bokemeyer, M Ghiani, A Fuchs, Barthold Deiters, Fraence Hardtstock, A Brandes, J Knop, Hans-Dieter Orzechowski, Thomas Wilke
Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting. International journal of colorectal disease 35 (8) (2020)